BioSpace News Archive

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced details from preclinical poster presentations at the Alzheimer’s Association International Conference (AAIC) 2022.

AditxtScore can help physicians determine their patient’s immune status and appropriate timing for COVID-19 vaccination or boosting ~

Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it will report its second quarter financial results on Thursday, August 11th.

Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on August 1, 2022 that were approved by the Compensation Committee of its Board of Directors under Company’s 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 5 individuals hired by Acutus in July 2022.

Prothena Corporation plc announced that in connection with hiring a new employee, the compensation committee of the Company’s board of directors granted the individual hired by the Company an option to purchase 35,000 ordinary shares of the Company.

Aptose Biosciences Inc., a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, announced financial results for the three months ended June 30, 2022 and provided a corporate update.

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company’s second quarter 2022 financial results will be released after market close on Tuesday, August 9, 2022.

Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today provided a business update and reported financial results for the second quarter ended June 30, 2022.

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, will report second quarter 2022 financial and operating results after market close on Thursday, August 4, 2022.

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Wednesday, August 3, 2022, at 8:30 a.m. Eastern Time to report its second quarter 2022 financial results and corporate activities.